AstraZeneca Plc $AZN Shares Newly Purchased by Westpac Banking Corp

Westpac Banking Corp purchased a new stake in AstraZeneca Plc (NYSE:AZN – Free Report) during the third quarter, Holdings Channel reports. The institutional investor purchased 22,206 shares of the company’s stock, valued at approximately $3,623,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Aries Wealth Management grew its position in shares of AstraZeneca by 1.3% during the third quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock worth $741,000 after buying an additional 60 shares in the last quarter. Triumph Capital Management increased its stake in shares of AstraZeneca by 32.6% during the third quarter. Triumph Capital Management now owns 252 shares of the company’s stock worth $41,000 after buying an additional 62 shares during the period. Claro Advisors Inc. increased its stake in shares of AstraZeneca by 5.2% during the third quarter. Claro Advisors Inc. now owns 1,247 shares of the company’s stock worth $201,000 after buying an additional 62 shares during the period. Davis Investment Partners LLC raised its holdings in AstraZeneca by 3.4% in the third quarter. Davis Investment Partners LLC now owns 1,868 shares of the company’s stock valued at $302,000 after acquiring an additional 62 shares in the last quarter. Finally, Riversedge Advisors LLC raised its holdings in AstraZeneca by 2.9% in the third quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock valued at $379,000 after acquiring an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $175.34 on Friday. The stock has a 50 day moving average price of $170.44 and a 200 day moving average price of $180.08. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $271.94 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 1.39 and a beta of 0.24. AstraZeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71.

AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings results on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company had revenue of $16.21 billion for the quarter, compared to analyst estimates of $16 billion. During the same period in the prior year, the firm posted $2.38 earnings per share. The firm’s revenue was up 6.5% on a year-over-year basis. Research analysts predict that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AZN. Nordea Equity Research upgraded shares of AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. CICC Research started coverage on shares of AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price objective on the stock. Finally, Royal Bank Of Canada began coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating for the company. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

Check Out Our Latest Report on AstraZeneca

AstraZeneca Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Read More

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.